skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy

Review

(2094) Views  (767) Full article downloads

Authors: Samuel L Washington III, Alan W Shindel

Published Date August 2010 Volume 2010:4 Pages 159 - 171
DOI: http://dx.doi.org/10.2147/DDDT.S9067

Samuel L Washington III1, Alan W Shindel2

1School of Medicine, University of California at San Francisco, San Francisco, California, USA; 2Department of Urology, University of California at San Francisco, San Francisco, California, USA

Abstract: Selective phosphodiesterase type 5 inhibitors (PDE5Is) have revolutionized the ­treatment of erectile dysfunction (ED) in men. As an on-demand treatment, PDE5Is have excellent efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, these drugs do have side-effect profiles that are troublesome to some patients, eg, headache, dyspepsia, myalgia, etc. Furthermore, many patients and their partners dislike the necessity of on-demand treatment for ED, citing a desire for greater spontaneity with sexual interactions. In 2008, approximately 10 years after the release of the first commercially available PDE5I, a paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil by the US Food and Drug Administration for the management of ED. The prolonged half-life of tadalafil lends itself well to this dosing regimen and conveys the advantage of separating medication from sexual interactions; lower dose therapy also carries the theoretical benefit of lower incidence of side effects. In this study, we review the current state of the art with respect to this new management strategy for ED, highlighting published reports of the efficacy and tolerability of the daily dose tadalafil regimen.

Keywords: PDE5 inhibitor, on-demand therapy, side effects, daily dosing
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University